Articles By Rob Wright, Chief Editor
I Just Love A Good Turnaround Success Story
IBM and GE are some famous business-focused turnaround stories, but this month we;’ve got a memorable one from the biopharma industry.
When A Pandemic Provides You Lemons
Just as COVID changed our personal lives, it forced us to make changes to Life Science Leader, too. Ultimately, it is the reader who benefits from these changes, because we’re bringing you more of the content you want in more ways.
Two Immigrants, One Unique Plan For A Biopharma
This is the story of how an intrapreneur and an entrepreneur came together to cofound and co-lead a pharmaceutical company that leverages the best of what the U.S. and China have to offer toward discovering and developing new oncology therapeutics.
Are We On The Precipice Of Unprecedented Collaboration In Biopharma?
The recent announcement of Sanofi agreeing to help produce Pfizer's COVID-19 vaccine could represent biopharma's entry into a period of unprecedented collaboration.
Let’s Talk About JPM 2021
Rob Wright, chief editor of Life Science Leader, shares thoughts on attending the 39th Annual J.P. Morgan Healthcare Conference (JPM) which was 100% virtual this year.
What Went Right In 2020? My Top 5 List
Life Science Leader's Rob Wright reviews five things that went right in 2020.
New Year, New President, New Outlook
New Year’s is not just a time of celebration, but a point at which we step out of the day-to-day to reflect on how we did — and resolve to do better.
Frank Gupton – Revolutionizing Pharma Manufacturing From The Outside In
“I’ve gotten more press during the last six and a half months than in my 68 years on this earth,” jokes Frank Gupton, Ph.D., a professor at Virginia Commonwealth University who has been involved in some key recent developments in pharma manufacturing.
How A First-Time Pharma CEO Faces Hypergrowth
Jeffrey Nau, Ph.D., discusses the career path that led him to becoming president and CEO of Oyster Point Pharma, a publicly traded biopharma now valued at more than $550 million and on the brink of commercial launch.